Safety and efficacy of Lipo B on cutaneous warts

• Research type

  Research Study

• Full title

  A study to evaluate the safety and efficacy of Liposome-Encapsulated Bleomycin(Lipo-BTM) on cutaneous warts

• Contact name

  Sunil Chopra

• Sponsor organisation

  Barking Havering and Redbridge NHS Trust

• Eudract number

  2008-005950-19

• ISRCTN Number

  Not submitted

• Research summary

  A wart is generally a small, rough tumour, typically on hands and feet that can resemble a cauliflower or a solid blister. Warts are common, and are caused by a viral infection, specifically by the human papillomavirus (HPV) and are contagious when in contact with the skin of another. It is also possible to get warts from using towels or other objects. They typically disappear after a few months but can last for years and can recur. Warts are easily spread from person to person by skin-skin contact. They are benign growths, which characteristically do not have any malignant tendencies. Currently, there are numerous medications both prescribed and over the counter, however, the wide range of medications and no standardised treatment usually means that many of the treatments are not consistently successful. Thus a non-painful easily applicable topical gel preparation, which is clinically effective and eradicates the wart, is of much clinical importance. Research into the efficacy of treatment must take into account the possibility of spontaneous regression. Warts in adult, in those with a long duration of infection are less likely to resolve spontaneously and are more recalcitrant to treatment. Bleomycin has been shown to be effective against warts when injected intra-lesionally. With the use of a liposomal formulation we expect the bleomycin sulphate to be delivered without the need for any injections.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  09/H0720/93

• Date of REC Opinion

  12 Aug 2009

• REC opinion

  Further Information Favourable Opinion